The Pulse
OpenEvidence Raises $250 Million at a $15 Billion Valuation
OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation, Business Insider reported on September 24, 2026. The financing follows a January round that valued the medical AI company at $12 bill
AI.info Team ·
A $3 billion valuation increase since January
OpenEvidence has raised $250 million at a $15 billion valuation, Business Insider reported on September 24, citing people familiar with the matter. Hospital systems and Andreessen Horowitz participated in the financing, the report said. The company was valued at $12 billion in a round announced in January.
The new valuation marks a $3 billion increase in roughly eight months. Business Insider did not identify the participating hospital systems or disclose the terms of the latest financing. The report also does not provide revenue, profitability, or other financial measures that would let readers assess the valuation against the company’s business.
Doctors are the audience for OpenEvidence’s search engine
OpenEvidence makes an AI-powered search engine for doctors. The product is designed to answer clinical questions using medical information, including evidence that can inform diagnosis and treatment. That focus gives the company a specific role in clinical work: helping medical professionals find and interpret information, rather than selling a general-purpose chatbot.
Business Insider reported that OpenEvidence was founded in 2022 and is based in Miami. The company has described its product as “the fastest-growing application for physicians in history,” according to the report. That is the company’s own characterization; the financing story does not supply an independent adoption figure or a methodology for comparing its growth with other physician tools.
Large AI companies are building healthcare products
The funding comes as OpenAI, Anthropic and other AI companies expand their work in healthcare, Business Insider reported. The article points to a broader shift from providing underlying models to developing healthcare applications. OpenEvidence’s existing medical search product could make it strategically relevant to companies seeking a direct foothold with clinicians, though the report does not say any such company has made an offer.
Business Insider also said OpenEvidence could be open to a sale that includes access to computing resources. But the outlet said it could not verify whether potential acquirers had expressed interest, and noted the company may prefer to remain independent. That possibility is separate from the reported financing and should not be read as evidence that a sale process is underway.
The financing report leaves key details unanswered
Business Insider said OpenEvidence has raised more than $1 billion over the past year, naming Thrive Capital, DST, GV, Kleiner Perkins and Sequoia among its investors. The report did not break down how much of that total came from each backer, or specify how the new $250 million will be used. It also did not establish whether the latest valuation reflects a completed transaction with newly issued shares or another financing structure.
The $15 billion figure puts a price on investor expectations for a company selling AI-powered medical search, but the report offers no operating metrics to show how those expectations compare with current results. For now, the clearest benchmark is the rise from January’s $12 billion valuation to the $15 billion reported for the new round.